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Gram-Scale Synthesis of the (±)-Sparteine Surrogate and (±)-
Sparteine 
James D. Firth,[a] Steven J. Canipa,[a] Leigh Ferris[b] and 3HWHU2¶%ULHQ*[a]
Abstract: An 8-step, gram-scale synthesis of the (±)-sparteine 
surrogate (22% yield, with just 3 chromatographic purifications) and a 
10-step, gram-scale synthesis of (±)-sparteine (31% yield) are 
reported. Both syntheses proceed with complete diastereocontrol and 
allow access to either antipode. Since the syntheses do not rely on 
natural product extraction, our work addresses long-term supply 
issues relating to these widely used chiral ligands. 
The natural product sparteine and its structurally related 
cousin, the sparteine surrogate (Scheme 1) developed in our 
laboratory,[1] are widely used chiral ligands in asymmetric 
synthesis. ,Q SDUWLFXODU WKHVH GLDPLQHV DUH WKH ³JR-WR´ FKLUDO
ligands for organolithium bases such as s-BuLi[2] for use in 
reactions pioneered in the 1990s by Hoppe[3] and Beak.[4] The 
more recent work from the Aggarwal group on programmable 
assembly-line synthesis[5] using chiral boron reagents (generated 
from s-BuLi/chiral diamine-mediated asymmetric lithiations) has 
significantly expanded the synthetic potential offered by sparteine 
and the sparteine surrogate.  
Both (±)- and (+)-sparteine are naturally occurring[6] and are 
thus commercially available, although the availability of each 
antipode has varied over the last 20 years![7] They can also be 
obtained from the alkaloid lupanine via a resolution procedure,[8] 
recently patented by Maulide et al.[9] In contrast, only the (+)-
sparteine surrogate is commercially available but, due to its high 
price, it is best obtained E\RXUJURXS¶Vgram-scale synthesis from 
the natural product (±)-cytisine.[10] The main issue with all of these 
sources of sparteine/sparteine surrogate is that they rely on 
natural product extractions and this can lead to supply issues (as 
observed for (±)- and (+)-sparteine over the last few years).[7] 
Indeed, during the development of the hepatitis C drug, Telaprevir, 
researchers at Vertex rejected a process-scale route that used 
the (+)-sparteine surrogate VLQFH³LQTXLULHVDERXWORQJ-term, high-
volume supply of (±)-cytisine had been met with concerns about 
production variability, due mainly to reliance on (±)-cytisine 
isolation froPQDWXUDOVRXUFHV´[11]  
The lack of adoption of the (+)-sparteine surrogate by process 
chemists at Vertex re-ignited our desire to develop a new 
synthesis of the sparteine surrogate that would allow access to 
both antipodes on a gram-scale. Furthermore, the sparteine 
surrogate has a much broader synthetic scope than sparteine due 
to a greatly enhanced reactivity of the s-BuLi/sparteine surrogate 
complex. For example, the high reactivity of the s-BuLi/sparteine 
surrogate complex was required for one of the steps in $JJDUZDO¶V
recently completed total synthesis of (±)-stemaphylline[12] and was 
crucial for the high yielding lithiation-trapping of N-Boc 
piperidine.[13]  
Over the years, our group[10,14] and others[15] have explored 
synthetic approaches to enantiopure (+)- and (±)-sparteine 
surrogate. However, all approaches are either inconveniently long, 
lack diastereo- and/or regioselectivity, only allow access to one 
enantiomer and/or proceed with overall low yields. These 
limitations have thus far precluded the synthesis of enantiopure 
(+)- and (±)-sparteine surrogate on a gram-scale and addressing 
this is the primary topic of this paper. In addition, in designing our 
new approach to the sparteine surrogate, we also recognized that 
it could also be adapted to deliver a new resolution-reconnection 
strategy for the gram-scale synthesis of (±)-sparteine. Despite 
numerous syntheses of racemic sparteine over 65 years,[16] there 
are only two enantioselective syntheses (by Aubé[17] and our 
group[18]) which delivered ~50 mg quantities of (+)- or (±)-
sparteine over long or low yielding approaches.  
Our retrosynthetic analyses and design concepts are shown 
in Scheme 1. We envisaged that the (±)-sparteine surrogate 
would be derived from quinolizidine 3 via reduction and N-
methylation; the quinolizidine ring would be constructed from 2 by 
deprotection and conjugate addition of the amine to the D,E-
unsaturated nitrile, where we predicted that axial protonation of 
the intermediate nitrile anion would set the required cis relative 
stereochemistry for bispidine formation. Diastereoselective 
alkylation (precedented with other electrophiles[19]) of piperidine 
(R)-1 obtained by enzymatic resolution[20] would deliver nitrile 2.  
 
Scheme 1. Retrosynthetic analysis of (±)-sparteine surrogate and (±)-sparteine. 
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For (±)-sparteine, we realized that the two resolved 
enantiomers of 1 could, if they were recombined, make up the 
entire (±)-sparteine skeleton except for the bridging methylene 
group. Therefore, separation and recombination of 1, with 
methylene incorporation, would lead to a highly connective 
synthesis of enantiopure (±)-sparteine from a simple racemic 
starting material that had been resolved into its two enantiomers. 
We anticipated that this resolution-recombination strategy should 
improve the efficiency of our earlier (±)-sparteine synthesis which 
proceeded via the same strategy.[18] In our planned route, (±)-
sparteine would be derived from bis-ester 5 by N-deprotection, 
amide formation and reduction. A Michael reaction of the enolate 
of (R)-1 and DE-unsaturated ester (S)-4 (itself crafted from (S)-1 
with the extra methylene unit) would give bis-ester 5. The relative 
stereochemistry in 5 would be assured if the reaction (enolate 
Michael addition and enolate protonation) followed the same 
diastereoselectivity as in enolate alkylations.[18,19]  
The optimized synthesis of the (±)-sparteine surrogate is 
shown in Scheme 2. Using a known method,[14b,c] racemic ester 
rac-1 was synthesised by pyridine hydrogenation and Boc 
protection in 90% yield over 2 steps on a 30 g scale (no 
chromatography, see SI for details). Using conditions optimized 
from a related literature protocol,[20] treatment of ~10 g batches of 
racemic 1 with lipase from Burkholderia cepacia, in a mixture of 
THF and phosphate buffer (pH 7.0) at 35 °C , resulted in the 
isolation (after simple filtration and aqueous work-up, no 
chromatography) of acid (S)-6 (49%, 98:2 er) and enantiopure 
ester (R)-1 (46%, >99:1 er).  
With significant quantities of (R)-1 in hand, attention turned to 
construction of the full carbon skeleton of the (±)-sparteine 
surrogate. We initially explored the use of a bis-ester analogue of 
3 but the end-game was less efficient than that via 3 (see SI for 
details). Installation of the acrylonitrile and the accompanying 
stereocentre was achieved through alkylation of the lithium 
enolate derived from (R)-1 with 2-bromomethylacrylonitrile 7,[15c] 
giving 2 in 93% yield (after chromatography) as a single 
diastereomer, without any reduction in er. At this stage, the 
relative stereochemistry of 2 was assigned based on .QLJKW¶V
precedent.[19] Subsequent Boc cleavage followed by an 
intramolecular conjugate addition reaction between the resulting 
amine and D,E-unsaturated nitrile gave key quinolizidine 3 in 84% 
yield (after chromatography) as a single diastereomer. The 
relative stereochemistry was identified by X-ray 
crystallography.[21] Interestingly, quinolizidine 3 adopts a cis-
decalin conformation with the ester and nitrile substituents 
adopting equatorial positions. Assuming that the nitrile anion 
formed after conjugate addition adopts a conformation similar to 
this X-ray structure, then axial protonation on the less sterically 
hindered top face would account for the observed 
diastereoselectivity.  
With all three stereocentres set, we then formed the bispidine 
framework of the (±)-sparteine surrogate. Selective reduction of 
the nitrile of quinolizidine 3, with in situ generated nickel boride, 
and concomitant lactamisation gave 8.[15c] The structure of 8 was 
confirmed by single crystal X-ray diffraction[21] and clearly showed 
the trans-decalin framework. Thus, ring flipping via nitrogen 
inversion can allow the aminomethyl and ester groups to adopt 
the required axial positions for cyclisation (compare with the X-ray 
structure of 3). Next, methylation of lactam 8 with NaH and MeI 
proceeded well, giving 9 in 72% (after chromatography) over 2 
steps and completing the skeleton of the (±)-sparteine surrogate. 
Reduction of the lactam 9 initially proved problematic, with the use 
of LiAlH4[14a] or borane[22] giving complex mixtures. Gratifyingly, 
the use of DIBAL-H resulted in clean reduction of the lactam, 
giving 3.5 g of the (±)-sparteine surrogate in 93% yield after 
distillation. The optical rotation ([Į@D ±29.2 (c 1.0, EtOH)) mirrored 
that of semi-synthetic (+)-sparteine surrogate ([Į@D +29.7 (c 1.1, 
EtOH)[10]). Of note, this gram-scale, fully diastereocontrolled 
synthesis proceeded in 22% overall yield over 8 steps[23] from 
commercially available materials, with only 3 chromatographic 
separations and one distillation utilised.  
 
 
 
Scheme 2. Multigram synthesis of the (±)-sparteine surrogate. 
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Scheme 3. Total synthesis of (±)-sparteine. 
 
We also used piperidines (S)-6 and (R)-1 in a total synthesis 
of (±)-sparteine (Scheme 3); in this case, all intermediates except 
5 were purified by chromatography. Acid (S)-6 was re-esterified 
under Steglich conditions, giving (S)-1 in 94% yield. Next, 
installation of the requisite methylene group was achieved 
through the use of EschenmRVHU¶VVDOW(QROL]DWLRQZLWK/iHMDS 
followed by trapping gave amine 10 as a single diastereomer in 
92% yield. The relative stereochemistry in 10 has not been proven 
but is likely to be as shown based on related alkylations (vide 
infra). Methylation and DBU-mediated elimination gave D,E-
unsaturated ester (S)-4 in 92% yield, with no racemization. 
Disappointingly, all attempts to add an enolate derived from Boc-
protected (R)-1 to (S)-4 resulted in the generation of complex 
mixtures of products. Therefore, we resorted to switching the 
protecting groups. Benzyl protected piperidines (S)-11 and (R)-12 
were obtained in 97% and 91% yields from (S)-1 and (R)-1 
respectively. Gratifyingly, using conditions based on a related 
example from the literature,[22] treatment of (R)-12 with LDA at ±
78 °C before addition of D,E-unsaturated ester (S)-11 led to a 
successful Michael addition to give 5, with complete control over 
the two newly-formed stereocentres. The stereoselectivity 
presumably arises due to the Michael addition and protonation of 
the intermediate enolate following the same sense of induction as 
previously reported enolate alkylations.[18,19] Debenzylation of 13 
under transfer hydrogenolysis conditions, was followed by in situ 
bis-lactamisation (upon addition of K2CO3), giving lactam 13 as a 
single diastereomer in 69% over 2 steps, on a gram-scale. The 
relative stereochemistry was confirmed by single crystal X-ray 
diffraction.[21] Amide reduction completed the synthesis of (±)-
sparteine, which was isolated as the bisulfate salt,[24] after 
recrystallization, in 67% yield.[25] The optical rotation (of the free 
base, [Į]D ±20.4 (c 1.0, EtOH)(lit.,[17] ([Į@D ±20.7 (c 1.8, EtOH)) 
confirmed that (±)-sparteine had been synthesied. Overall, this 
diastereocontrolled synthesis of (±)-sparteine was completed in 
10 steps (longest linear sequence[23]) in 31% yield.  
In summary, we have presented a unified strategy for the 
gram-scale synthesis of the (±)-sparteine surrogate and the lupin 
alkaloid (±)-sparteine, with full control over relative and absolute 
stereochemistry. The modular nature of the routes facilitates the 
synthesis of either antipode of the sparteine surrogate and 
sparteine and thus addresses any long-term supply issues 
relating to these synthetically useful chiral ligands.  
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